This volume presents state-of-the-art information on each of the arms of the unfolded protein response (UPR), how their activation/repression are regulated, integrated, and coordinated, how UPR components affect cancer cell biology and responsiveness to therapeutic interventions, and how UPR components/activities offer potentially novel targets for drug discovery, repurposing, and development. The volume will provide the most recent information on the signaling and regulation of the UPR, explore examples of how the UPR and/or specific components contribute to cancer biology, and identify and explore specific examples of potently new actionable targets for drug discovery and development from within the UPR and its regulation. Unique to the volume will be a specific focus on the UPR and its role in cancer biology, as well as a discussion of the role of the UPR in drug responses and resistance in cancer.

Recent studies have highlighted that epithelial-mesenchymal transition (EMT) is not only about cell migration and invasion, but it can also govern many other important elements such as immunosuppression, metabolic reprogramming, senescence-associated secretory phenotype (SASP), stem cell properties, therapy resistance, and tumor microenvironment interactions. With the on-going debate about the requirement of EMT for cancer metastasis, an emerging focus on intermediate states of EMT and its reverse process mesenchymal-epithelial transition (MET) offer new ideas for metastatic requirements and the dynamics of EMT/MET during the entire metastatic cascade. Therefore, we would like to initiate discussions on viewing EMT and its downstream signaling networks as a fulcrum of cellular plasticity, and a facilitator of the adaptive responses of cancer cells to distant organ microenvironments and various therapeutic assaults. We hereby invite scientists who have prominently contributed to this field, and whose valuable insights have led to the appreciation of epithelial-mesenchymal plasticity as a more comprehensive mediator of the adaptive response of cancer cells, with huge implications in metastasis, drug resistance, tumor relapse, and patient survival.

An overview of the current systems biology-based knowledge and the experimental approaches for deciphering the biological basis of cancer.

Introduces readers to key case studies that illustrate how theory and data can be integrated to understand wildlife disease ecology.

The scope of the book is very broad, covering a wide range of areas in HBV/HDV and HCV research, including both basic and clinical science. The selected topics range from epidemiology, immunology, molecular virology and oncology, to clinical therapy.Chronic Hepatitis B and C consists of 14 chapters, each being a review of a special topic on HBV or HCV. While review articles on a special topic can be found in periodical journals, they tend to be more restricted in presentation. Therefore, this book will provide more in-depth coverage of what are presented as "unpublished results" and "data not shown" in journal articles. Furthermore, several authors in this book do not write review articles regularly. Some authors wrote reviews on a specific topic regularly, but they tried a new topic in this book (e.g., Dr. YF Liaw on "natural course," Dr. Shih on "virion release," Dr. Michael Lai on "lymphotropism of HCV," etc. ⋯). Overall, the book will offer useful information at the cutting age.Sample Chapter(s)